Meridian Bioscience Inc
NASDAQ:VIVO
Meridian Bioscience Inc
Operating Income
Meridian Bioscience Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Meridian Bioscience Inc
NASDAQ:VIVO
|
Operating Income
$75.6m
|
CAGR 3-Years
25%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Cooper Companies Inc
NYSE:COO
|
Operating Income
$536.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
5%
|
CAGR 10-Years
5%
|
|
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
Operating Income
$281m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
Align Technology Inc
NASDAQ:ALGN
|
Operating Income
$663.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
14%
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Operating Income
$474.4m
|
CAGR 3-Years
541%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
See Also
What is Meridian Bioscience Inc's Operating Income?
Operating Income
75.6m
USD
Based on the financial report for Sep 30, 2022, Meridian Bioscience Inc's Operating Income amounts to 75.6m USD.
What is Meridian Bioscience Inc's Operating Income growth rate?
Operating Income CAGR 5Y
11%
Over the last year, the Operating Income growth was -26%. The average annual Operating Income growth rates for Meridian Bioscience Inc have been 25% over the past three years , 11% over the past five years .